All In Biotech

Drug Trial Radar · NCT05643638

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

65

Actual

Start

Mar 4, 2024

Primary completion

Mar 17, 2026

Study completion Jun 17, 2026

Sponsor

Lead sponsor
Cynata Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Dec 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.

Conditions

  • Graft Versus Host Disease, Acute

Interventions

  • CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)Biological

    Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.

  • PlaceboBiological

    The placebo product is identical to CYP-001, except that it contains no active agent

  • CorticosteroidsDrug

    All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: 28 days

Locations

39 sites in 7 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Phoenix, Arizona

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • University of Arkansas Medical Center

    Little Rock, Arkansas

  • Mayo Clinic Hospital

    Jacksonville, Florida

  • Memorial healthcare System

    Pembroke Pines, Florida

  • BMT Group of Georgia

    Atlanta, Georgia

  • Northwestern University

    Evanston, Illinois

  • Karmanos Cancer Institute

    Detroit, Michigan

  • University Of Nebrasaka Medical Center

    Omaha, Nebraska

  • Weill Cornell Medicine - New York Presbyterian Hospital

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Penn State Health

    Hershey, Pennsylvania

  • University of Utah

    Salt Lake City, Utah

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Hospital Claude Huriez

    Lille, France

  • Hôpital Necker Enfants Malades

    Paris, France

  • Hôpital Universitaire Pitié-Salpêtrière

    Paris, France

  • Azienda Ospedaliero Universitaria delle Marche

    Ancona, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Istituto Clinico Humanitas

    Rozzano, Italy

  • IRCCS Ospedale Casa Sollievo della Sofferenza

    San Giovanni Rotondo, Italy

  • Ospedale dell'Angelo di Mestre

    Venezia, Italy

  • Vilnius University Hospital Santaros Klinikos

    Vilnius, Lithuania

  • ICO l'Hospitalet - Hospital Duran i Reynals

    Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitato De La Princesa

    Madrid, Spain

  • Hospital Universitario Virgen de la Arrixaca

    Murcia, Spain

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • Anadolu Medical Center

    Eskişehir, Turkey (Türkiye)

  • Gayrettepe Florence Nightingale Hastanesi

    Istanbul, Turkey (Türkiye)

  • Koc University

    Istanbul, Turkey (Türkiye)

  • Memorial Bahcelievler Hospital

    Istanbul, Turkey (Türkiye)

  • Izmir Medicalpark Hospital

    Izmir, Turkey (Türkiye)

  • İnonu University

    Malatya, Turkey (Türkiye)

  • Dr Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi

    Yenimahalle, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.